Aspen’s new diabetes injection has been approved in South Africa, with sales expected within months. The company has not yet announced a local price, leaving patients waiting to see what another treatment option will cost.

In a JSE SENS announcement on 11 November, Aspen said it had received approvals in South Africa and Brazil. Canada had already approved the product, as announced in July.

The injection contains semaglutide, the same active ingredient used in Ozempic and the weight-loss medicine Wegovy. Aspen’s announced approval is for adults with type 2 diabetes, alongside diet and exercise, to help control blood sugar. Its announcement does not report approval for weight loss.

Approval comes before the pharmacy shelf

Aspen said sales in all three countries were expected “over the next few months”. It did not provide a specific South African launch date, a selling price or details of medical-scheme cover.

For someone budgeting for treatment, those gaps matter. There is no announced price to compare with an existing prescription, and the statement does not establish that the product is available at pharmacies today.

The medicine works by copying a hormone the body releases after eating. SAHPRA explains that this helps lower blood sugar and can also reduce appetite. The right product and treatment still need a healthcare professional’s assessment.

Why this matters for Aspen

The approvals bring Aspen’s generic diabetes injection closer to sale in three markets. The next test is whether it can supply and launch the product on the timetable it has set out.

Aspen’s September annual-results statement shows why approval and launch should be tracked separately. At that point, the company said its Canadian launch depended on the supply of the medicine’s active ingredient from Dr. Reddy’s Laboratories. Wednesday’s notice does not give a new supply-volume figure.

That earlier Canadian supply condition should not be presented as a newly announced South African shortage. It does show that regulatory permission is only one part of getting a medicine to patients.

What patients can check next

When launch details arrive, useful questions for a prescriber or pharmacist will include the approved product and dose, the total treatment cost, availability and any medical-scheme requirements.

SAHPRA’s patient guidance says medicines containing this ingredient should be obtained on prescription from a licensed medical practitioner and through licensed pharmacies or dispensers. Buying outside the legal supply chain carries risks, including falsified or contaminated products.

SBL analysis: Approval brings Aspen closer to launching another diabetes treatment. What it means for patients will become clearer when there is a launch date, reliable stock and a published price. Any claim about how much South Africans will save is premature.

KEEP READING